Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

In vivo and in vitro characterization of GL0034, a novel long-acting glucagon-like peptide-1 receptor agonist

Title: In vivo and in vitro characterization of GL0034, a novel long-acting glucagon-like peptide-1 receptor agonist
Authors: Jones, B; Burade, V; Akalestou, E; Manchanda, Y; Ramchunder, Z; Carrat, G; Nguyen-Tu, M-S; Marchetti, P; Piemonti, L; Leclerc, I; Thennati, R; Vilsboll, T; Thorens, B; Tomas, A; Rutter, GA
Source: 2101 ; 2090
Publisher Information: Wiley
Publication Year: 2022
Collection: Imperial College London: Spiral
Description: Aims To describe the in vitro characteristics and antidiabetic in vivo efficacy of the novel glucagon-like peptide-1 receptor agonist (GLP-1RA) GL0034. Materials and Methods Glucagon-like peptide-1 receptor (GLP-1R) kinetic binding parameters, cyclic adenosine monophosphate (cAMP) signalling, endocytosis and recycling were measured using HEK293 and INS-1832/3 cells expressing human GLP-1R. Insulin secretion was measured in vitro using INS-1832/3 cells, mouse islets and human islets. Chronic administration studies to evaluate weight loss and glycaemic effects were performed in db/db and diet-induced obese mice. Results Compared to the leading GLP-1RA semaglutide, GL0034 showed increased binding affinity and potency-driven bias in favour of cAMP over GLP-1R endocytosis and β-arrestin-2 recruitment. Insulin secretory responses were similar for both ligands. GL0034 (6 nmol/kg) led to at least as much weight loss and lowering of blood glucose as did semaglutide at a higher dose (14 nmol/kg). Conclusions GL0034 is a G protein-biased agonist that shows powerful antidiabetic effects in mice, and may serve as a promising new GLP-1RA for obese patients with type 2 diabetes.
Document Type: article in journal/newspaper
Language: English
Relation: Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics; http://hdl.handle.net/10044/1/103696
DOI: 10.1111/dom.14794
Availability: http://hdl.handle.net/10044/1/103696; https://doi.org/10.1111/dom.14794
Rights: © 2022 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. ; http://creativecommons.org/licenses/by/4.0/
Accession Number: edsbas.A86185EB
Database: BASE